MedTrace Logo

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

NCT00177671 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2013-02-06

Study results available
· View outcomes & findings →

Summary

This study will determine the effectiveness of combining escitalopram, venlafaxine, or duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory, concentration, attention, and problem solving abilities, and reducing the risk of depressive relapse in older individuals with depression.

Conditions

Interventions

DRUG

Escitalopram

Escitalopram, 10mg to 20mg daily.

DRUG

Donepezil

Donepezil, 5mg to 10mg daily.

DRUG

Venlafaxine

Venlafaxine, 150mg to 300mg daily.

DRUG

Placebo

DRUG

Duloxetine

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Bruce G. Pollock, MD, PhD · University of Pittsburgh Professor of Psychiatry, Pharmacology, and Nursing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00177671 on ClinicalTrials.gov